Date: 2013-01-28
Type of information: Series D financing round
Company: Bone Therapeutics (Belgium)
Investors: Nausicaa Ventures (Belgium) BAMS Angels Fund I (Belgium) Life Science Research Partners (Belgium) Société Régionale d\'Investissement de Wallonie (SRIW) (Belgium) Sambrinvest (Belgium)
Amount: €7.7 million
Funding type: Series D financing round
Planned used: These funds will be used to accelerate bone cell therapy platform, especially Phase III clinical development of Bone Therapeutics\' unique bone cell therapy product PREOB®.
Others: Bone Therapeutics, abiopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, has successfully closed a Series D funding round, raising €7.7 million from current investors and the Walloon Region. The funds raised will be used to further accelerate the development of Bone Therapeutics\' unique bone cell therapy pipeline, as well as sustain the ongoing Phase III clinical trials for Bone Therapeutics\' lead product PREOB®. PREOB® is an autologous bone cell therapy product which is in Phase III clinical trials for the treatment of osteonecrosis and non-union fractures. Bone Therapeutics\' cell therapy approach seeks to significantly improve upon current standard of care for bone diseases. All Bone Therapeutics\' cell products are unique as they are osteoblastic (i.e., bone-forming) and require a minimally invasive administration technique, avoiding the need for surgery.
The Series D round was supported by Bone Therapeutics\' existing private and institutional investors (Nausicaa Ventures, BAMS Angels Fund I and Life Science Research Partners) as well as the Société Régionale d\'Investissement de Wallonie (SRIW) and Sambrinvest, two supportive Walloon Region controlled minority shareholders.
Therapeutic area: Bone diseases
